logo

Japan Oral Anti-Diabetic Drug Market Size (2024 - 2029)

The Japan Oral Anti-Diabetic Drug Market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes, particularly type 2, which is influenced by the country's aging population and lifestyle factors such as inactivity and irregular eating patterns. The market's expansion is further supported by the rising number of diagnoses linked to metabolic syndrome screenings aimed at preventing lifestyle-related disorders. As diabetes becomes more prevalent, the demand for oral anti-diabetic medications is expected to rise, reflecting the market's growth trajectory.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Japan Oral Anti-Diabetic Drug Market Market Size

Market Size of Japan Oral Anti-Diabetic Drug Industry

Japan Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 2.42 Billion
Market Size (2029) USD 3.02 Billion
CAGR (2024 - 2029) 4.60 %

Major Players

Japan Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

Japan Oral Anti-Diabetic Drug Market Analysis

The Japan Oral Anti-Diabetic Drug Market size is estimated at USD 2.42 billion in 2024, and is expected to reach USD 3.02 billion by 2029, growing at a CAGR of 4.60% during the forecast period (2024-2029).

Japan's oral anti-diabetic drug market is on a growth trajectory, bolstered by a surge in diabetes cases and proactive industry measures, such as enhanced product offerings and expanded production capacities.

Given the escalating diabetic population in Japan, the demand for diabetes drugs and devices, pivotal for blood glucose management, is expected to increase. Data from the IDF Diabetes Atlas reveals a widespread distribution of diabetes across age groups, with a notable concentration among the working-age demographic. In 2022, Japan had 5.5 thousand diabetic people under 20, 43.3 thousand aged 20-59, and 30.5 thousand above 60. Such a high concentration of diabetic people in the working-age bracket significantly impacts the country's economic healthcare burden. The IDF Diabetes Atlas projects Japan's total diabetes-related health expenditure to reach USD 32.8 million by 2030.

Japan's aging demographic, which is vulnerable to diseases, coupled with a rise in obesity due to sedentary lifestyles and irregular eating habits, are key drivers behind the nation's escalating diabetes rates. As of December 2023, approximately 30% of Japan's population was aged 65 or older, as highlighted by the Ministry of Internal Affairs and Communications in May 2024. With this aging trend, Japan is bracing for a further uptick in diabetes cases, which would lead to increased demand for oral anti-diabetic drugs.

The increasing prevalence of diabetes, driven by an aging population and lifestyle factors, is expected to significantly boost the market for oral anti-diabetic drugs in Japan.

Japan Oral Anti-Diabetic Drug Industry Segmentation

Oral anti-diabetes drugs help manage blood glucose levels in patients whose bodies still produce some insulin, such as those with type 2 diabetes. 

The Japanese oral anti-diabetic drug market is segmented by drugs and end users. By drug, the market is segmented into biguanides, alpha-glucosidase inhibitors, glucagon-like peptide-1(GLP-1) receptor agonists, sodium-glucose cotransport-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and others. By end user, the market is segmented into hospitals/clinics, personal/home care settings, and others. The report offers the value (USD) for all the above segments.

By Drug Type
Biguanides
Alpha-Glucosidase Inhibitors
GLP-1 Receptor Agonists
SGLT-2 Inhibitors
DPP-4 Inhibitors
Others
By End Users
Hospitals/Clinics
Personal/Home Care Settings
Others
Need A Different Region Or Segment?
Customize Now

Japan Oral Anti-Diabetic Drug Market Size Summary

The Japan oral anti-diabetic drug market is poised for significant growth, driven by the increasing prevalence of diabetes, particularly type 2 diabetes, among the aging population. The rise in diabetes cases is attributed to factors such as a sedentary lifestyle, obesity, and dietary changes, which have led to a higher incidence of insulin resistance. The market is characterized by the presence of major global pharmaceutical companies like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals, which are focusing on innovative drug developments to cater to the growing demand. The approval of new medications, such as SGLT2 inhibitors, has expanded treatment options for patients with type 2 diabetes, especially those with cardiovascular risks. This expansion is expected to drive market growth during the forecast period.

The market landscape is further shaped by the consolidation of key players and their strategic collaborations to enhance product offerings. For instance, partnerships like that between Sanofi and Health2Sync aim to integrate technology with diabetes management, improving patient adherence and monitoring. Additionally, the introduction of new drugs, such as Twymeeg by Sumitomo Dainippon Pharma, highlights the ongoing innovation within the market. As dietary patterns continue to evolve, with a shift towards more westernized diets, the demand for oral anti-diabetic drugs is anticipated to rise, supporting the market's expansion in the coming years.

Explore More

Japan Oral Anti-Diabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence Of Diabetes

      2. 1.2.2 Reimbursement Policies For Diabetes Oral Medications

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Requirements For Product Approval

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Drug Type

      1. 2.1.1 Biguanides

      2. 2.1.2 Alpha-Glucosidase Inhibitors

      3. 2.1.3 GLP-1 Receptor Agonists

      4. 2.1.4 SGLT-2 Inhibitors

      5. 2.1.5 DPP-4 Inhibitors

      6. 2.1.6 Others

    2. 2.2 By End Users

      1. 2.2.1 Hospitals/Clinics

      2. 2.2.2 Personal/Home Care Settings

      3. 2.2.3 Others

Japan Oral Anti-Diabetic Drug Market Size FAQs

The Japan Oral Anti-Diabetic Drug Market size is expected to reach USD 2.42 billion in 2024 and grow at a CAGR of 4.60% to reach USD 3.02 billion by 2029.

In 2024, the Japan Oral Anti-Diabetic Drug Market size is expected to reach USD 2.42 billion.

Japan Oral Anti-Diabetic Drug Market Report Snapshots

Japan Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)